Howard Capital Management (New York)’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Howard Capital Management (New York)’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,000	Closed	-$9K	–	108
2016 Q2	$9K	Hold	2,000	–	–	﹤0.01%	101
2016 Q1	$11K	Hold	2,000	–	–	﹤0.01%	91
2015 Q4	$34K	Hold	2,000	–	–	0.01%	86
2015 Q3	$42K	Hold	2,000	–	–	0.01%	87
2015 Q2	$99K	Hold	2,000	–	–	0.02%	91
2015 Q1	$157K	Sell	2,000 -150	-7%	-$9.3K	0.03%	92
2014 Q4	$130K	Sell	2,150 -100	-4%	-$5.02K	0.03%	93
2014 Q3	$96K	Hold	2,250	–	–	0.02%	90
2014 Q2	$139K	Buy	2,250 +1,000	+80%	+$58.1K	0.03%	96
2014 Q1	$81K	Buy	+1,250	New	+$84.5K	0.02%	95

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Howard Capital Management (New York)'s OREX Position: Q3 2016 in Review

Howard Capital Management (New York) sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 2,000 shares — an estimated $9K sold.

Howard Capital Management (New York) first reported a position in OREX in Q1 2014 and held it in 10 quarters. The position peaked at $157K in Q1 2015. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

Howard Capital Management (New York) reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Howard Capital Management (New York) sold 2,000 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $9K.
Howard Capital Management (New York) first reported a position in Orexigen Therapeutics, Inc. in Q1 2014 and held it in 10 quarters.
Howard Capital Management (New York)'s Orexigen Therapeutics, Inc. position peaked at $157K in Q1 2015.
55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Howard Capital Management (New York)'s 13F filing for Q3 2016, filed 25 Oct 2016.